




RealRate

PHARMACEUTICAL 2021

International Stem Cell CORP Rank 316 of 402





RealRate

PHARMACEUTICAL 2021

International Stem Cell CORP Rank 316 of 402



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 99% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is -52%, being 100% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,183
Cost of Goods Sold	2,781
Intangible Assets	1,262
Liabilities, Current	1,483
Liabilities, Non-Current	845
Other Assets	1,308
Other Compr. Net Income	0
Other Expenses	1,755
Other Liabilities	2,992
Other Net Income	94
Other Revenues	7,128
Property and Equipment	534
Research and Development	988
Selling, General and Administrative Expense	4,422

Output Variable	Value in 1000 USD
Assets	5,287
Liabilities	5,320
Expenses	9,946
Revenues	7,128
Stockholders Equity	-33
Net Income	-2,724
Comprehensive Net Income	-2,724
Economic Capital Ratio	-52%